SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is facing intense volatility following a mixed earnings report where record revenue and AI growth were overshadowed by the surprise announcement that long-time CEO Shantanu Narayen will step down. The community remains deeply divided, with bulls pointing to a low forward P/E and profitable fundamentals as a generational buying opportunity, while bears argue that generative AI tools are cannibalizing the core business and eroding the company's long-term competitive moat.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is generating significant buzz as traders closely watch a potential breakout past key resistance levels, with the community fueled by long-standing speculation regarding its integration into X payments and broader crypto bull market sentiment. Discussions are dominated by varying perspectives, ranging from optimistic 'moon' targets and loyalty among long-term holders to skepticism from those labeling recent price action as typical volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors rally behind a major production milestone for its M-ceNK cell therapy platform, which establishes a scalable pathway for large-scale NK cell manufacturing and cryopreservation. The community is heavily focused on the company's progress toward commercializing its pipeline, with widespread discussion regarding upcoming FDA regulatory milestones, expansion into global markets, and active efforts to initiate a short squeeze against heavy short interest.

Trump For President

The TRUMP crypto token is currently trending as community members aggressively debate whether the asset represents a genuine political-financial movement or a recurring pump-and-dump scheme. Discussions are heavily polarized, with supporters highlighting upcoming high-profile events and potential for growth, while critics dismiss the project as a grift tied to broader controversies surrounding political influence and wealth distribution.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is experiencing heightened volatility as investors grapple with conflicting reports surrounding the conflict in the Middle East and concerns over persistent inflation data. The community remains deeply divided, with many traders debating whether recent market fluctuations are merely tactical traps set by market makers or genuine shifts in economic sentiment as they await further clarity on PCE metrics.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne shares are facing significant volatility and negative sentiment as investors weigh a landmark revenue milestone against concerns over decelerating growth and management transitions. The community remains deeply divided, with some traders optimistic about the company's long-term position in the cybersecurity sector, while others are frustrated by consistent underperformance and high stock-based compensation.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Markets are under significant pressure as geopolitical tensions in the Middle East and concerns over persistent inflation following GDP and PCE data keep investors on edge. The community is actively debating the sustainability of current valuations, with many traders discussing potential further downside and positioning for increased volatility as energy supply risks remain a central talking point.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending amid extreme volatility and record-breaking trading volumes, driven by escalating conflict in the Middle East and the closure of the Strait of Hormuz. Community discussion is heavily divided between bulls anticipating $200 per barrel due to sustained supply shocks, and bears warning of a potential 'rug pull' as diplomatic efforts and strategic reserve releases struggle to cool energy markets.

PayPay Corp. engages in the development and provision of electronic payment services that include mobile payment. The company was founded on June 15, 2018 and is headquartered in Tokyo, Japan.

PayPay Corp - ADR - Sponsor

PayPay

PayPay is drawing significant attention following its high-profile Nasdaq debut, with retail traders and institutional investors like ARK Invest closely tracking the fintech's volatility. The community remains divided on whether the stock presents a compelling entry point or a speculative "hot potato" trade following its initial pricing below the expected range.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is drawing intense focus as community members weigh the potential impact of new Canadian EV rebates and a European energy retail license against ongoing concerns about cash burn, dilution risks, and intense competition from rivals. While some traders are closely watching for a bounce off technical support levels, others remain skeptical about the firm's pivot toward AI and robotics given its current delivery and market dynamics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Quadrature Capital Ltd Boosts Stock Holdings in argenex SE $ARGX

Quadrature Capital Ltd raised its position in shares of argenex SE (NASDAQ:ARGX - Free Report) by 146.8% in the third quarter, according to its most recent Form 13F filing with the Securities and...

Van ECK Associates Corp Sells 5,527 Shares of argenex SE $ARGX

Van ECK Associates Corp lessened its stake in shares of argenex SE (NASDAQ:ARGX - Free Report) by 13.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional...

argenex SE $ARGX Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC raised its holdings in shares of argenex SE (NASDAQ:ARGX - Free Report) by 28.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities...

First Trust Advisors LP Acquires 6,215 Shares of argenex SE $ARGX

First Trust Advisors LP grew its holdings in shares of argenex SE (NASDAQ:ARGX - Free Report) by 10.6% in the third quarter, according to its most recent Form 13F filing with the Securities and...

Sands Capital Management LLC Takes $12.26 Million Position in argenex SE $ARGX

Sands Capital Management LLC bought a new position in shares of argenex SE (NASDAQ:ARGX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and...

Capital World Investors Buys 8,422 Shares of argenex SE $ARGX

Capital World Investors increased its holdings in shares of argenex SE (NASDAQ:ARGX - Free Report) by 0.4% during the third quarter, according to its most recent 13F filing with the Securities and...

Capital International Sarl Invests $1.36 Million in argenex SE $ARGX

Capital International Sarl acquired a new stake in argenex SE (NASDAQ:ARGX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission...

argenex (NASDAQ:ARGX) Upgraded by Deutsche Bank Aktiengesellschaft to Buy Rating

Deutsche Bank Aktiengesellschaft raised argenex from a "hold" rating to a "buy" rating in a report on Tuesday...

<ul class="summary-bullets"><li>The “go” decision was reached early, ahead of the company’s second quarter expected timeline.</li><li>The results from the interim analysis appear stronger than those reported by Sanofi's experimental drug riliprubart in its open-label mid-stage CIDP study, Truist said.</li><li>H.C. Wainwright increased its view of the probability of launch for claseprubart to 35% from a previous 26%.</li></ul>Shares of Dianthus Therapeutics, Inc. (DNTH) soared 19% on Monday after the company announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) program, boosting Wall Street optimism.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-early-go-decision-following">said</a> that the decision was based on an analysis of data from a part of its late-stage trial in which a response rate of 50% or greater was observed. Twenty or more responders were confirmed out of the first 40 participants to complete part A of the trial and no related serious infections or discontinuations were observed, the company said.The “go” decision was reached early, ahead of the company’s second quarter expected timeline, and confirmed by an independent Data Safety Monitoring Board review, it added.The decision supports continued development of claseprubart into the pivotal portion of the trial in CIDP, the company said. Dianthus Therapeutics said that it will maintain the dose as is in the part A portion of the trial and engage with regulators to remove a lower dose arm in the part B portion.Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare, acquired autoimmune disorder where the immune system damages the myelin sheath of peripheral nerves, causing progressive or relapsing muscle weakness, numbness, and sensory loss. Other firms developing drugs for the condition include Sanofi (SNY) and Argenx SE (ARGX).<h2 class="st-heading-2">Wall Street Responds</h2>Truist raised the firm's price target on Dianthus to $110 from $63 and kept a ‘Buy’ rating on the shares. The results from the interim analysis appear stronger than those reported by Sanofi's experimental drug riliprubart in its open-label mid-stage CIDP study, the analyst told investors in a research note.H.C. Wainwright analyst Swayampakula Ramakanth, meanwhile, raised the firm's price target on Dianthus to $130 from $47 and kept a ‘Buy’ rating on the shares. The firm increased its view of the probability of launch for claseprubart to 35% from a previous 26% and also raised its price estimate to $450,000 per patient per annum compared to its prior $250,000 estimate.TD Cowen, which views Dianthus as "a viable takeout target," also kept a ‘Buy’ rating on the shares.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around DNTH stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/DNTH">DNTH stock</a> has more than tripled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/jim-cramer-terrific-ai-stock-pick-gev-gets-double-upgrade/cZdVrjXRIIw">Jim Cramer's 'Terrific' AI Stock Pick Is Already Up 26% YTD, And It Just Received A Double Upgrade Today — Here's Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Dianthus Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch

Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of its late-stage trial. 

Equity

argenex (NASDAQ:ARGX) Given "Outperform" Rating at Wedbush

Wedbush reiterated an "outperform" rating and issued a $1,000.00 price objective on shares of argenex in a research note on Monday...

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

Current Price	$708.85
Prev Close	$728.09
Open	$721.18
Dividend Yield	0.00%
50-Day Moving Average	$807.90
Beta	0.61
Avg. Volume	374,626.07
PE Ratio	33.60

52-Week High	$934.62
52-Week Low	$510.06
Market Capitalization	$43.87B
EPS (Annual)	$21.14
Price to Book	7.11
Revenue Per Employee	$2.6M

ARGX
Argenx

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARGX News

ARGXArgenx